16.09.2020     19:45–20:45

ePoster-Session 1 – PS-1: SARS-CoV-2


ePoster-Session 1 – PS-1: SARS-CoV-2

PS-1-1 Side-by-side comparison of three serological test methods for the humoral immune response against SARS-CoV-2
Bernd Jahrsdörfer (Ulm)

PS-1-2 Consensus on preparation of SARS-CoV-2 convalescent plasma
Birgit Gathof (Köln)

PS-1-3 Impact of SARS-CoV-2 on blood supply in two large University Hospitals
Christian Temme (Essen)

PS-1-4 Characterization of convalescent immune plasma of COVID-19 patients
Viola Hähnel (Regensburg)

PS-1-5 Prevalence and neutralizing activity of antibodies against SARS-CoV-2 in a population of donors of COVID-19 convalescent plasma
Heiko Rühl (Bonn)

PS-1-6 Investigating the correlation between symptom severity and antibody titer in COVID-19 convalescent plasma donors
Thomas Ossner (Regensburg), Robert Offner (Regensburg)

PS-1-7 Anti-SARS-CoV-2 virus antibody levels in putative convalescent plasma donors after COVID19 recovery
Tanja Vollmer (Bad Oyenhausen)

PS-1-8 First data of donor recruitment and donor qualification for the production of immunoplasma of convalescents after COVID19 infection at the University Hospital Erlangen, starting from 01.04.2020
Susanne Achenbach (Erlangen)

PS-1-9 Blood group O protective for Covid-19 infection? ABO-Blood group and severity of Covid-19 disease
Julia Neuhann (Köln)

PS-1-10 Online verification of donor eligibility to reduce SARS-CoV-2 infection risk due to blood donation
Malte Ziemann (Lübeck)

PS-1-11 Changes of antibody titer after repeated donations of convalescent plasma by donors recovered from COVID-19
Adelina-Florina Bica (Regensburg), Robert Offner (Regensburg)

PS-1-12 Screening donors for donating SARS-CoV-2 convalescent plasma
Leonard Rose (Köln)

PS-1-13 Assessment of hypercoagulation in COVID-19 patients using thrombelastography
Karina Althaus (Tübingen)

PS-1-14 Fibrinolysis shut down in COVID-19 patients: Report of a severe case with potential diagnostic and clinical relevance
Tamam Bakchoul (Tübingen)